

Introduction of Collagen Matrix

The next generation of tissue regenerative technology.

CEO: DJ Hsieh

November 29, 2017



About CEO: DJ Hsieh

Education

➤ Ph. D, Cell & Molecular Biology, SUNY at Buffalo

Current Position

- > CEO, ACRO Biomedical Co., Ltd.
- ➤ Adjunct Professor, National Kaohsiung Marine University
- ➤ Director of Academia-Industry Consortium for Southern Taiwan Science Park/ Director of Taiwan Supercritical Fluid Association/Taiwan Biotechnology Industry Alliance/ Supervisor of The Allied Association for Science Park Industries

History

- CEO, Sunmax Biotechnology
- > Deputy CEO, Institute for biotechnology and medicine industry(IBMI)
- Director of Business Development, Animal Technology Institute Taiwan
- > CEO, PRIT Biotech
- Founder/CEO, Acrobio Investment Consulting Co. Ltd.
- ➤ Associate Professor, Kaohsiung Medical University



Introduction of ACRO Biomedical

ACRO Biomedical was founded in June, 2014, and is positioning in developing and producing biomaterials for the applications in tissue engineering and regenerative medicine (TERM). Using its proprietary super critical CO2 (SCCO2) technology to remove cells, fats and non-collagenous proteins in animal organs and tissues , while keeping the intact collagen scaffolds as the products for the high-end medical devices.

- ➤ In 2016, the world's first successful canine corneal transplantation was conducted.
- >In the leading position in global tissue engineering with advance technique and complete product pipelines.
- ➤In May 2017, received FDA 510K and TFDA class II medical device approval for Collagen Matrix product.
- ➤ In November 2017, received TFDA class II medical device approval for Bone Graft product.

Company	ACRO Biomedical Co., Ltd.	
Chairman	Wang, Lu-Yen	
Factory Location	3rd Fl., No. 57, Luke 2nd Rd., Lujhu Dist., Kaohsiung City 82151, Taiwan	
Established date	June, 2014	
Paid-up Capital	NTD 206.7 millions (~USD7M)	
Company positioning	develop and produce medical devices for the use in tissue engineering and regenerative medicine	
Total employee	25	

Milestones of ACRO Biomedical

June 2014	Company established by a group of scientists, professors, doctors and angel investors		
July 2015	Constructed GMP qualified factory in the Biotech area of Kaohsiung Science Park		
August 2015	Acquired license for Manufacture and Sale of Therapeutic Medical Device Products		
May 2016	Received International Management System Certificate- ISO13485		
June 2016	Received GMP management system approval for medical device from Taiwan FDA		
June 2016	Submitted product registration for TFDA Medical Device: Collagen Matrix		
August 2016	Submitted product registration for USFDA Medical Device: Collagen Matrix		
September 2016	Acquired licenses of 4 Class I Medical Device products from TFDA		
September 2016	Launched ACRODERM skin care series products		
September 2016	Conducted the world's first successful canine corneal transplantation		
November 2016	Interviewed and broadcasted by Discovery Channel of cornea project and the case on corneal transplantation		
November 2016	Qualified as the Emerging Biotech company by Ministry of Economic Affair		
April 2017	Acquired CE Mark licenses of 4 Class I Medical Device products		




Milestones of ACRO Biomedical

April 2017	Submit product registration for TFDA Medical Device: Bone Graft, 6/1 submit to USFDA		
May 2017	5/10 received FDA510K for Collagen Matrix product		
May 2017	5/16 received TFDA class II Medical Device approval for Collagen Matrix product		
Sept. 2017	Initiate IRB-approved human clinical test in Kaohsiung Veteran General Hospital for Collagen Matrix product.		
October 2017	Sign distribution agreement for Collagen Matrix Taiwan market with Jinglun Incorporation.		
October 2017	Submit product registration for TFDA Medical Device: Dental Bone Graft, 6/1 submit to USFDA		
November 2017	License out Collagen Ophthalmic Matrix to Oculus BioMed for Australian/New Zealand market		
November 2017	11/8 receive TFDA approval for class II medical device Bone Graft product.		
November 2017	Receive National Innovation Award for Collagen Ophthalmic Matrix product.		




Three Elements for TERM





Tissue Engineering






Important Features of Scaffolds

- 1. Biocompatibility
- 2. Biodegradability
- 3. Mechanical properties
- 4. Scaffold architecture
- 5. Manufacturing technology
- 6. Choices of biomaterial



Collagen Scaffolds



Collagen

- Collagen makes up 25~35 % of the total amount of proteins in human body.
- •Collagen can be found almost everywhere in the body, such as skin, bone, cartilage, ligament, muscles and connective tissue.
- Scientists refer collagen as the glue that holds the body together.








Collagen: Triple-helix Structure

Collagen Structure



Hydroxyproline and lysine of polypeptide bond with enzymes to aid cross-linking, forming Fiber from Fibril.


Multiple Microfibril are lined parallelly to form Fibril.

Multiple Tropocollagen molecules accumulated to form Microfibril.

Collagen is the most abundant protein in human body which forms different structures with specific mechanical strength or flexible web-like structure.



Collagen Structure



between different species

high potential to trigger immunogenic reaction within human body


Determinants

high potential to trigger immunogenic reaction within human body

Determinants



Atelocollagen








comparable to human collagen with smaller concern over immunogenic reaction.




Traditional Process



The loose collagen is reconstructed using chemical cross-linking agents

Products made by traditional process





Disadvantages of Traditional Processed Collagen

Other processes to make decellularized collagen scaffolds

Strong Acids

Strong Alkali

SDS

Organic Solvents

Collagen structure is loose due to the absence of C-Terminal and N-Terminal; thus in the traditional process, chemical cross linking agents are used to strengthen the structure

1 Time, space and money consuming

Atelocollagen can be easily bio-degraded, so it's hard to reach the time length requirement of the product.

C-Terminal and N-Terminal are hard to be removed completely, and the residues would cause allergic reaction.

Most of the chemical cross linking agents are carcinogens, and often cause allergic reaction.

Reconstruction of collagen cannot duplicate the porosity and mechanical strength of natural collagen scaffold.



Proprietary Technology


The Proprietary Technology- Supercritical CO₂ is used to remove cells, fats and other substances in animal organs and tissues, while keeping the undiminished collagen scaffolds as the product for the high-end medical devices.

Minimum Manipulation!!






Phase diagram of CO₂



Critical Factors of scCO₂ Technology



Temperature/Pressure/Speed/ Static-Dynamic Extraction/ Cycle Times and Duration

Collagen structures after scCO₂ process

- - ETC 10.0kV 10.3mm x10.0k SE


- Easy and low cost
- High efficiency and safe
- Sterilization and virus deactivation
- Green (no pollution) and can be apple to different organs and tissues



Core Technology- Supercritical CO₂

Supercritical CO₂

SPF Pig





5000-5L Supercritical CO2 Extraction System

Medical Devices

Item	Use	Picture
Bone Graft for Dental Use	Augmentation or reconstructive treatment of the alveolar ridge	
Collagen Membrane for Dental Use	Barrier between soft and hard tissue	
Bone Graft	Bone filler for bony voids or gaps	
Collagen Matrix	Wound Dressing for ulcers and wounds	
Collagen Ophthalmic Matrix/Artificial Cornea	Matrix for reconstructing corneal structure	
Dermal Filler	Injected filler to reduce or eliminate wrinkles	-
Spinal Cord	Biomaterial for spinal trauma repair	





Product Category

- Wound Care: Collagen Matrix, Collagen Matrix Powder, Collagen Membrane,
 Scar Spray, Scar Care Dressing,
 External Aesthetic Restoration Prothesis
- Orthopedics: Bone Graft (granule, cube, bullet shape)
- Dentistry: Bone Graft and Collagen Membrane
- Ophthalmology: Collagen Ophthalmic Matrix, Collagen Biocornea
- Aesthetic Medicine: Collagen Dermal Filler
- Medical Devices for Companion Animals
- Others: Atelocollagen, Skin Care Products, Research Materials



Collagen Matrix and Collagen Matrix Powder







Product Description

Product Name

ABCcolla® Collagen Matrix

TFDA: Class II; I. 4018

FDA Product Code: KGN •



TFDA Spec

■ 1 cm x 2 cm	■ 1" × 2"
■ 2 cm x 2 cm	■ 1.5" × 1.5"
■ 2 cm x 3 cm	■ 1" x 1.5"
■ 3 cm x 4 cm	■ 1.5" x 2"
■ 5 cm x 5 cm	■ 2" × 2"

FDA Spec

■ 1 cm x 2 cm	■ 1 cm x 5 cm	■ 1" × 2"
■ 2 cm x 2 cm	■ 2 cm x 5 cm	■ 1.5" × 1.5"
■ 2 cm x 3 cm	■ 3 cm x 5 cm	■ 1" × 1.5"
■ 3 cm x 4 cm	■ 3 cm x 10 cm	■ 1.5" × 2"
■ 5 cm x 5 cm	■ 5 cm x 10 cm	■ 2" × 2"



About ABCcolla® Collagen Matrix

Description

The Collagen Matrix is the decellularized porcine hide, and consists mainly type I collagen.

Features of the Collagen Matrix

- 1. Intact collagen scaffolds for wound healing and tissue regeneration
- 2. Biocompatible and self-absorbable
- 3. Absorb exudates and keep the wound bed moisture
- 4. For use: rehydrate before applying to the wound



Physicochemical Properties

	Item	Criteria	Result
1	Collagen Source	Porcine dermis	
2	Trace impurities	<50 ppm (ASTM F1185)	PASS
3	Residual DNA	< 50 ng/mg sample	PASS
4	Sterilization	Gamma Irradiation, SAL <10 ⁻⁶	PASS
5	Collagen content	>500 ug/mg	PASS
6	Absorbency	$>12 \text{ g}/100 \text{ cm}^2$	PASS
7	Endotoxin	<20 ED/device	PASS



Biocompatibility Test

Regulation	Item	Result
ISO 10993-5	Cytotoxicity	PASS
ISO 10993-10	Sensitization	PASS
ISO 10993-10	Irritation or Intracutaneous Reactivity	PASS
ISO 10993-11	Acute Systemic Toxicity	PASS
<usp> 151</usp>	Material-Mediated Pyrogenicity	PASS
ISO 10993-11	Subchronic Toxicity	PASS
ISO 10993-3	Genotoxicity (Ames, MLA)	PASS
ISO 10993-6	Implantation	PASS
ISO 10993-4	Hemocompatibility	PASS
USP38-NF33 <85>	Endotoxin Test	PASS
ICH Q5A	Virus Inactivation Study	PASS




Viral Reduction Test

Viral Reduction Test	Viral Reduction Factor (log ₁₀)			
VII al Neduction Test	BPIV	PRV	Reovirus 3	PPV
Value	≥9.336	≥9.980	≧8.399	≧13.172

The result of the viral reduction test of all four viruses passes the standard:
 (log₁₀) ≥6 logs, which is regulated by ICH Q5A.



Animal Performance Test



The result indicated that the wound healing rate is similar but slightly faster than the predicate device.

Wound No.	Sham	CollaWound	ABCcolla
Day 7	Part to DEFECTION	Part No. (1) 22 PERSON	Part No Maria
Day 14	Section 1 Programme Progra	A Till Park Manager Land Manage	Path No.
Day 21	Park No.	Property of the Control of the Contr	And the Control of th
Day 28	PART NO CONTRACTOR	Prom No CONTRACTOR	All from the second sec

Wound healing process on pig.


The result showed better wound healing and had less scar formation.




No Immunogenic Protein


Alpha-gal stain


Porcine tissue





Collagen Matrix










H&E


H&E stain





Type I collagen stain










Collagen Matrix- SEM


Vertical section





Surface









Collagen Matrix- SEM

Vertical section




Surface






Collagen Matrix- SEM






Cells cultured on the Matrix

DAPI- HSF cell






Cell Proliferation- 3T3 cells





TFDA Certificate (May 16, 2017)





FDA510K, K162348



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

May 10, 2017

Acro Biomedical Co., Ltd Dar-Jen Hsieh CEO 3f., No.57, Luke 2nd Rd, Lujhu Dist. Kaohsiung City, 82151 TW

Re: K162348

Trade/Device Name: ABCcolla Collagen Matrix

Regulatory Class: Unclassified

Product Code: KGN Dated: April 10, 2017 Received: April 10, 2017



Indication (USFDA)

The Matrix is intended for the management of wounds including:

- Partial and full thickness wounds
- Venous ulcers
- Pressure ulcers
- Diabetic ulcers
- Tunnels/undermined wounds
- Surgical wounds
- Trauma wounds
- First and second-degree burns
- Draining wounds




ABCcolla® Collagen Matrix Case Reports

Patient was injured by Forklift truck: Severe traumatic wound and bone fracture Wound Size 12cm x 8 cm

Day 0: Severe wound site





Day 3: No infection



Day 3: Attached ABCcolla® Collagen Matrix to accelerate wound healing process.



First day applying Collagen Matrix to the wound site

Day 8:

5 days after applying ABCcolla® Collagen Matrix to the wound, the majority of the matrix was degrade, and as the arrows show, the tissues had grown and started to heal.



The fifth day after applying Collagen Matrix to the wound site

Wound from removing the skin for the self skin grafting Wound size: 15cmX20cm

Day 0: The Collagen Matrix was applied to the wound made by removing patient's skin for the skin grafting.







Day 7: 7 days after applying the matrix to the wound, the matrix was completely self-absorbed, and the wound site was almost fully recovered with no scar formation.




ABCcolla® Collagen Matrix Case Reports

Day 1 (Sep. 19): Apply **ABCcolla® Collagen Matrix** to the wound on the arm, and artificial skin (X brand) to upper arm and back of the hand for the comparison.



Day 7: Wound covered with ABCcolla Collagen Matrix had recovered well with no more exudates, while the site using artificial skin (X brand) are still wet, and the wound site was injured when changing the covered material.







ABCcolla Collagen Matrix used for Soft Tissue Augmentation



After 14 Days










Other Possible Application

Other than trauma wounds, ulcers, and soft tissue augmentation, this Collagen Matrix can also be applied to

- Tendon Repair
- Phalloplasty
- Breast Reconstruction
- Partial mastectomy
- Meninges (for brain surgery)





THANK YOU

